Retatrutide Side Effects: What the 2026 Trial Data Show

Retatrutide's most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. In the phase 2 obesity trial of 338 adults, these were dose-dependent, mostly mild to moderate, and worst during dose escalation. Trials also showed a small rise in resting heart rate and some skin-tingling sensations. Retatrutide is still investigational in 2026, so this is research data, not a product pru offers. Wanting to get ahead of your metabolic health is a smart instinct, and there are supervised options you can start today.

What are retatrutide's most common side effects?

Most retatrutide side effects are digestive and dose-dependent. In the phase 2 obesity trial published in the New England Journal of Medicine, the frequent ones were nausea, diarrhea, vomiting, and constipation. They were usually mild to moderate, showed up most during dose increases, and often eased as the body adjusted. Trials also recorded a modest heart-rate rise and skin-tingling sensations in some people.

Retatrutide is an investigational drug from Eli Lilly. As of 2026 it is still in trials, so everything here is trial data, not a product you can be prescribed. pru does not offer retatrutide. For an FDA-cleared prescribing path today, people use compounded semaglutide or tirzepatide through a licensed pharmacy.

Why retatrutide causes these side effects

Retatrutide is a triple agonist. It acts on three gut and metabolic receptors at once: GLP-1, GIP, and glucagon. That triple action is what drives strong appetite and weight effects in trials, and it also explains the side-effect pattern. The GLP-1 and GIP signals slow the stomach and change appetite, which is where nausea and other gut symptoms come from. The glucagon signal raises energy use and is linked to the heart-rate and skin-sensation effects seen in trials.

The single-receptor GLP-1 medicines many people know work on just one of these pathways. Retatrutide's extra glucagon action is the main reason its side-effect profile differs from a plain GLP-1 drug. For a fuller picture of the drug itself, see the retatrutide guide.

Retatrutide nausea and gastrointestinal effects

Nausea is the most reported retatrutide side effect, and it rises with dose. In the phase 2 trial, nausea climbed from about 14% of people at the low 1 mg dose to as high as 60% at the top 12 mg dose. Vomiting reached about 21% and diarrhea about 33% at higher doses. Constipation also appeared. Most of these events were mild to moderate and tended to settle with continued dosing.

The pattern matters more than any single number. Gut symptoms concentrate in the first week or two after each dose step, then usually improve at a steady dose. The same is true for the GLP-1 medicines pru offers today. If you want practical tactics for settling the stomach, our GLP-1 nausea management guide covers timing, food, and hydration steps used with compounded semaglutide and tirzepatide.

Retatrutide and heart rate: what trials show

Retatrutide raised resting heart rate by a small, dose-dependent amount in trials. The average increase was roughly 5 to 10 beats per minute, and it peaked around week 24 before declining. A modest heart-rate rise is seen across the GLP-1 drug class, but retatrutide's increase tended to be at the higher end, likely tied to its glucagon action.

In the phase 2 data, this heart-rate change was not linked to more serious cardiac events. The serious adverse event rate was about 4%, similar to placebo. Phase 2 trials are not large enough to rule out rare heart risks, so dedicated cardiovascular outcome trials in the ongoing TRIUMPH phase 3 program will carry more weight once complete.

Skin tingling and other reported effects

Beyond the gut and heart rate, trials flagged a few other effects. Dysesthesia, a tingling or altered skin sensation, showed up in about 21% of people at the 12 mg dose. It appears connected to the glucagon-receptor action and is more common with retatrutide than with single-receptor GLP-1 drugs. Injection-site reactions, fatigue, and reduced appetite were also reported.

None of these are unique reasons to panic, but they are reasons the drug belongs under medical supervision. Retatrutide's side-effect list overlaps a lot with the approved GLP-1 medicines, with the skin sensation and heart-rate effects standing out as the differences. For contrast, see semaglutide side effects.

Is retatrutide safe?

In trials so far, retatrutide's safety profile looks broadly in line with other GLP-1 medicines, with most side effects mild to moderate and driven by dose. The key limit is data: retatrutide is investigational. It has not completed FDA review, and long-term safety in the general population is not yet established. Discontinuation because of side effects ranged from about 6% to 16% in phase 2, versus none on placebo.

The phase 3 TRIUMPH program is still reporting through 2026, including cardiovascular and organ-specific trials that will define the fuller safety picture. The reason pru does not offer retatrutide is regulatory: it is still pending FDA review and has no cleared, regulated compounding pathway yet. pru only offers peptides a licensed physician can prescribe and an FDA-registered 503A pharmacy can compound.

Until retatrutide reaches that kind of overseen, legitimate pathway, the sound move is to wait for it rather than order a research-only vial with no prescriber or pharmacy behind it, and to work with GLP-1 medicines a licensed pharmacy can lawfully compound today.

How side effects are managed in practice

The management playbook for GLP-1-class side effects is well understood, and it centers on going slow. Trials used stepwise dose escalation for a reason: it keeps most symptoms mild and gives the body time to adjust.

• Titrate slowly. Move up a dose only when the current one feels steady, guided by a prescriber.
• Eat smaller, lower-fat meals and stop at first fullness to blunt nausea.
• Stay hydrated and keep electrolytes up, especially with diarrhea or vomiting.
• Track resting heart rate and flag a sustained rise to your clinician.
• Report skin tingling, severe or lasting vomiting, or signs of dehydration promptly.

These same steps apply to the compounded semaglutide and tirzepatide pru offers. Dosing details for the investigational drug live in the retatrutide dosage explainer, and a head-to-head with an available option is in retatrutide vs tirzepatide.

Where retatrutide stands, and a grey-market warning

Retatrutide is not FDA approved and is not on the list of ingredients that 503A pharmacies may lawfully compound. Eli Lilly is expected to file for approval around late 2026, with a possible market launch no earlier than 2027 to 2028. That means there is no legitimate prescription or compounded retatrutide product available in 2026.

If you are researching where to get it, read where to buy retatrutide first for the full status. The safe, legal path to a GLP-1 today runs through a licensed prescriber and pharmacy, which is what pru is built around.

How pru handles GLP-1 side effects and safety

pru is a telehealth membership for compounded peptides. A licensed physician reviews your intake and confirms clinical fit, and an FDA-regulated 503A pharmacy fills the prescription. You select the therapy with guidance from pru's content; the physician confirms whether it is appropriate. Membership runs about $50 a month, and the medication is priced at cost and itemized, with no member markup. A higher dose costs a little more because it is more material, never because of a markup.

On weight and metabolic health, pru's live products are compounded semaglutide and compounded tirzepatide. These use the same active ingredients as well-known GLP-1 medicines, though a compounded product is not the same as any branded drug. They are pharmacy-grade and dispensed only after physician review, which is exactly the supervised setting where the side effects on this page can be managed safely.

pru does not currently offer retatrutide until there is a safe pathway for physician oversight and FDA-regulated 503A pharmacies. It is investigational, not compoundable, and not something a legitimate pharmacy can fill in 2026. If retatrutide interests you, the practical next step is a supervised GLP-1 you can start today.

Being proactive about your metabolic health is a smart, responsible move, and pru is built to make that supervised path the accessible one, with licensed physicians, pharmacy-grade medicine, and at-cost pricing. Take the next step when you are ready: browse the fat loss and metabolism options or see pricing.

Related reading

Keep going with these guides on retatrutide and the GLP-1 options available now:

• Retatrutide guide: what it is and how it works
• Retatrutide dosage and titration explained
• Retatrutide vs tirzepatide
• Where to buy retatrutide: the real status
• Managing GLP-1 nausea
• Semaglutide side effects
• Shop compounded GLP-1 options

Common questions